Anavex Life Sciences Files 2024 10-K

TL;DR

Anavex 10-K filed: FY24 results in, focus on ANAVEX 2-73 & 1-41 trials.

AI Summary

Anavex Life Sciences Corp. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its progress in developing treatments for neurodegenerative and neurodevelopmental disorders. The company's primary focus remains on its drug candidates, ANAVEX 2-73 and ANAVEX 1-41, with ongoing clinical trials and research. Financial details for the period, including revenue, expenses, and cash position, are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Anavex's financial health and operational progress in its drug development pipeline for neurological diseases.

Risk Assessment

Risk Level: medium — Biotech companies like Anavex face inherent risks related to clinical trial success, regulatory approvals, and market competition.

Key Players & Entities

• ANAVEX LIFE SCIENCES CORP. (company) — Filer of the 10-K
• 2024-09-30 (date) — Fiscal year end
• ANAVEX 2-73 (drug_candidate) — Key drug candidate mentioned
• ANAVEX 1-41 (drug_candidate) — Key drug candidate mentioned

FAQ

Key Financial Figures

• $0.001 — ection 12(b) of the Act: Common Stock, $0.001 par value AVXL NASDAQ Stock Market LL
• $5.09 — rter: $ 412 million based on a price of $5.09 per share, being the closing price of t
• $0.6 million — t from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multice

Filing Documents

• e6219_10-k.htm (10-K) — 1252KB
• e6219_ex19-1.htm (EX-19.1) — 27KB
• e6219_ex21-1.htm (EX-21.1) — 4KB
• e6219_ex23-1.htm (EX-23.1) — 3KB
• e6219_ex31-1.htm (EX-31.1) — 16KB
• e6219_ex31-2.htm (EX-31.2) — 14KB
• e6219_ex32-1.htm (EX-32.1) — 7KB
• image_001.jpg (GRAPHIC) — 285KB
• image_002.jpg (GRAPHIC) — 92KB
• 0001731122-24-002041.txt ( ) — 5376KB
• avxl-20240930.xsd (EX-101.SCH) — 31KB
• avxl-20240930_cal.xml (EX-101.CAL) — 29KB
• avxl-20240930_def.xml (EX-101.DEF) — 93KB
• avxl-20240930_lab.xml (EX-101.LAB) — 283KB
• avxl-20240930_pre.xml (EX-101.PRE) — 219KB
• e6219_10-k_htm.xml (XML) — 493KB

RISK FACTORS

ITEM 1A. RISK FACTORS 32

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS 62

CYBERSECURITY

ITEM 1C. CYBERSECURITY 62

PROPERTIES

ITEM 2. PROPERTIES 63

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS 63

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 64 PART II 64

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 64

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

ITEM 7 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION 64

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 70

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA F-1

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS 71

CONTROLS AND PROCEDURES

ITEM 9A. CONTROLS AND PROCEDURES 71

OTHER INFORMATION

ITEM 9B OTHER INFORMATION 71

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 71 PART III 72

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 72

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 77

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 83

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 86

PRINCIPAL ACCOUNTING FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 87 PART IV 88

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 88

FORM 10-K SUMMARY

ITEM 16. FORM 10-K SUMMARY 89 iii

Forward Looking Statements

Forward Looking Statements. This Annual Report on Form 10-K includes forward-looking regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "expect," "should," "forecast," "potential," "predict," "could," "would", "will", "suggest," "plan" and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: volatility in our stock price and in the markets in general; our ability to successfully conduct preclinical studies and clinical trials for our product candidates; our ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price; our ability to generate any revenue or to continue as a going concern; our ability to execute our research and development plan on time and on budget; our product candidates' ability to demonstrate efficacy or an acceptable safety profile; our ability to obtain the support of qualified scientific collaborators; our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale; our ability to identify and obtain additional product candidates; our reliance on third parties in non-clinical studies and clinical trials; our ability to defend against product liability claims; our ability to safeguard against security breaches; our ability to obtain and maintain sufficient intellectual property protection for our product candidates; our ability to comply with our intellectual property licensing agr

BUSINESS

ITEM 1. BUSINESS Overview and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS") diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials. Our focus is on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. We currently have two core programs and two seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases. The following table summarizes key information about our programs: * = Orphan Drug Designation by the FDA Anavex has a portfolio of compounds varying in sigma-1 receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX 2-73 (blarcamesine) target engagement or receptor occupancy with SIGMAR1 in the brain. 6 Source: Reyes S et al., Sci Rep. 2021 Aug 25;11(1):17150 Cellular Homeostasis Many diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular stress is possibly caused by the pre

View Full Filing

View this 10-K filing on SEC EDGAR